Barbara Vidal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Barbara Vidal has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Winterborn
Department of Biology, Queen’s University, Kingston, Ontario
1 shared publication Carol Hegadorn
Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada
1 shared publicationChristine Brown
Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada
1 shared publication- Christine Hough
Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada
1 shared publication - Colleen Notley
Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada
1 shared publication - David Lillicrap
Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON, Canada
1 shared publication
Latest Publications
- 26 June 2014
- Published by American Society of Hematology in Blood
- Vol. 123 (26) , 4045-4053
Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response
Ex vivo gene therapy strategies avoid systemic delivery of viruses thereby mitigating the risk of vector-associated immunogenicity. Previously, we delivered autologous factor VIII (FVIII)-expressing blood outgrowth endothelial cells (BOECs) to hemophilia A mice and showed that these cells remained sequestered within the implanted matrix and provided therapeutic levels of FVIII. Prior to translating this strategy into the canine (c) model of hemophilia A, we increased cFVIII transgene expression by at least 100-fold with the use of the elongation factor 1 alpha (EF1α) promoter and a strong endothelial enhancer element. BOECs isolated from hemophilia A dogs transduced with this lentiviral vector express levels of cFVIII ranging between 1.0 and 1.5 U/mL per 106 cells over 24 hours. Autologous BOECs have been implanted into the omentum of 2 normal and 3 hemophilia A dogs. These implanted cells formed new vessels in the omentum. All 3 hemophilia A dogs treated with FVIII-expressing autologous BOECs developed anti-FVIII immunoglobulin G2 antibodies, but in only 2 of the dogs were these antibodies inhibitory. FVIII antigen levels >40% in the absence of FVIII coagulant function were detected in the circulation for up to a year after a single gene therapy treatment, indicating prolonged cellular viability and synthesis of FVIII. Key Points Implanting autologous FVIII-expressing BOECs results in sustained FVIII antigen in hemophilia dogs. Anti-FVIII immunoglobulin G2 antibodies develop.
- 26 June 2014
- Published by American Society of Hematology in Blood
- Vol. 123 (26) , 4045-4053
Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response
Ex vivo gene therapy strategies avoid systemic delivery of viruses thereby mitigating the risk of vector-associated immunogenicity. Previously, we delivered autologous factor VIII (FVIII)-expressing blood outgrowth endothelial cells (BOECs) to hemophilia A mice and showed that these cells remained sequestered within the implanted matrix and provided therapeutic levels of FVIII. Prior to translating this strategy into the canine (c) model of hemophilia A, we increased cFVIII transgene expression by at least 100-fold with the use of the elongation factor 1 alpha (EF1α) promoter and a strong endothelial enhancer element. BOECs isolated from hemophilia A dogs transduced with this lentiviral vector express levels of cFVIII ranging between 1.0 and 1.5 U/mL per 106 cells over 24 hours. Autologous BOECs have been implanted into the omentum of 2 normal and 3 hemophilia A dogs. These implanted cells formed new vessels in the omentum. All 3 hemophilia A dogs treated with FVIII-expressing autologous BOECs developed anti-FVIII immunoglobulin G2 antibodies, but in only 2 of the dogs were these antibodies inhibitory. FVIII antigen levels >40% in the absence of FVIII coagulant function were detected in the circulation for up to a year after a single gene therapy treatment, indicating prolonged cellular viability and synthesis of FVIII. Key Points Implanting autologous FVIII-expressing BOECs results in sustained FVIII antigen in hemophilia dogs. Anti-FVIII immunoglobulin G2 antibodies develop.